Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ovid Therapeutics Inc. (OVID)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.9100+0.0300 (+1.60%)
At close: 04:00PM EDT
2.0100 +0.10 (+5.24%)
After hours: 05:41PM EDT
Advertisement

Ovid Therapeutics Inc.

1460 Broadway
Suite 15021
New York, NY 10036
United States
646 661 7661
https://www.ovidrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees49

Key Executives

NameTitlePayExercisedYear Born
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb BchirPres, CEO & Chairman847.07kN/A1953
Mr. Jeffrey A. RonaPrincipal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer613.18kN/A1968
Mr. Thomas Michael Perone J.D., M.B.A.Gen. Counsel, Chief Compliance Officer & Corp. Sec.632.11kN/A1965
Dr. Matthew J. During DSc, FACP, FRACP, M.D., Ph.D.Founder & Member of Scientific Advisory BoardN/AN/A1957
Mr. Jason Tardio M.B.A.Chief Operating OfficerN/AN/A1977
Ms. Lora PikeSr. Director of Investor Relations & PRN/AN/AN/A
Ms. Suzanne K. Wakamoto SHRM-SCP, SPHRSr. VP of HRN/AN/AN/A
Dr. Dirk HaasnerSr. VP of Global Manufacturing & CMC QAN/AN/A1965
Dr. Claude Nicaise M.D.Head of R&DN/AN/A1953
Mr. Luke RosenSr. VP of Accelerated Devel. & Community EngagementN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Corporate Governance

Ovid Therapeutics Inc.’s ISS Governance QualityScore as of June 1, 2022 is 9. The pillar scores are Audit: 7; Board: 8; Shareholder Rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement